Psychiatry A
Columbia Suicide Severity Rating Scale (C-SSRS)
Standardised tool for assessing suicidal ideation and behaviour. Used in emergency, inpatient, and outpatient settings. Recommended by FDA for clinical trials and widely adopted globally.
References
- Posner K et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
- FDA Guidance. Suicidality: Prospective Assessment of Occurrence in Clinical Trials. 2012.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.